Candidiasis, Chronic Mucocutaneous
"Candidiasis, Chronic Mucocutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy.
Descriptor ID |
D002178
|
MeSH Number(s) |
C01.539.800.200.100 C01.703.160.165 C01.703.295.165 C17.800.838.208.165
|
Concept/Terms |
Candidiasis, Chronic Mucocutaneous- Candidiasis, Chronic Mucocutaneous
- Candidiases, Chronic Mucocutaneous
- Chronic Mucocutaneous Candidiases
- Chronic Mucocutaneous Candidiasis
- Mucocutaneous Candidiases, Chronic
- Mucocutaneous Candidiasis, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Candidiasis, Chronic Mucocutaneous".
Below are MeSH descriptors whose meaning is more specific than "Candidiasis, Chronic Mucocutaneous".
This graph shows the total number of publications written about "Candidiasis, Chronic Mucocutaneous" by people in this website by year, and whether "Candidiasis, Chronic Mucocutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 0 | 2 | 2 |
2018 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Candidiasis, Chronic Mucocutaneous" by people in Profiles.
-
CARD9 Expression Pattern, Gene Dosage, and Immunodeficiency Phenotype Revisited. J Clin Immunol. 2022 02; 42(2):336-349.
-
Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency. J Clin Immunol. 2018 10; 38(7):753-756.
-
Novel signal transducer and activator of transcription 1 mutation disrupts small ubiquitin-related modifier conjugation causing gain of function. J Allergy Clin Immunol. 2018 05; 141(5):1844-1853.e2.
-
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017 May; 139(5):1629-1640.e2.